Objective: The renin-angiotensin-aldosterone system has become known as a prerequisite for tumor angiogenesis that is now recognized as a crucial step in the development of tumors, including cervical cancer. The Ang II-AT1R pathway is known to play an important role in tumor angiogenesis. MicroRNAs (miRNAs) are a class of small, regulating RNAs that participate in tumor genesis, differentiation and proliferation. The current study focused on the anti-tumor mechanism of olmesartan, a novel angiotensin II antagonist, on cervical cancer cells. 
Introduction
The renin-angiotensin-aldosterone system has become known as a prerequisite for tumors, including cervical cancer. 1 There are convincing data that angiotensin II (Ang II) stimulates cell proliferation in human cancer cell lines 2, 3 and induces angiogenesis via the upregulation of vascular endothelial growth factor (VEGF), which is one of the most potent angiogenic factors, 4, 5 via angiotensin type 1 (AT1) receptor stimulation. Thus, much attention has been paid to the blockade of the tumoral AT1 receptor as a novel molecular-targeted therapy. Olmesartan is a novel, strong and long-acting AT1 receptor antagonist. It is speculated that olmesartan might have capacity for the inhibition of cell growth and cell proliferation. 6 These studies create the potential mechanism that olmesartan can suppress the angiogenesis and cell proliferation in cervical cancer.
MicroRNAs (miRNAs) are small non-coding RNAs that play a prominent role in tumor genesis, differentiation and proliferation. miRNAs regulate gene expression by binding to 3' untranslated region (UTR). These genes are involved in a variety of biological cell processes. Current studies showed that miRNA acts as an oncogene or tumor suppressor gene in all kinds of cancer. miR-21 is one of the well-understood onco-miRNAs that promotes cancer proliferation, invasion and inhibition of tumor apoptosis by targeting programmed cell death 4 (PDCD4), phosphatase and tensin homolog (PTEN), B-cell CLL/lymphoma 2 (BCL2), tropomyosin 1 (alpha) (TPM1), tumor protein P53 (P53), and the transforming growth factor beta (TGF β) family. [7] [8] [9] miR-10b can also promote tumor invasion of breast cancer. 10 Previous studies have shown that miR-205 is a tumor-suppressing onco-miRNA. In human prostate cancer, miR-205 shows anti-tumor function by targeting protein kinase Cε. 11 Further, miR-205 inhibits breast cancer proliferation and promotes renal cancer cell apoptosis. 12 VEGF is a member of the platelet-derived growth factor (PDGF)/VEGF group. VEGF-A is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including angiogenesis and vasculogenesis. Previous studies indicate that VEGF is a positive regulator of tumor growth that promotes tumor migration and invasion, and inhibits tumor apoptosis. [13] [14] [15] It can be secreted by tumor cells acting on the endothelial cells of existing blood vessels to promote new blood vessel formation. Overexpression of VEGF has been detected in almost all human cancers investigated, such as glioma, prostate, lung, breast, renal, ovarian, and colorectal cancers. [16] [17] [18] [19] [20] [21] Therefore, VEGF is considered a potential therapy for cancer.
In the current study, olmesartan exhibited a high antiproliferation activity against cervical cancer. It was also found that olmesartan could promote miR-205 expression and inhibit VEGF-A expression. In addition, knocking down miR-205 and overexpression of VEGF-A can modulate the olmesartan sensitivity of cervical cancer. This result provides a new mechanism of olmesartan anti-tumor effect.
Material and methods

Cell culture and olmesartan treatment
HeLa and Siha cells were purchased from the American Type Culture Collection (Rockville, MD, USA) and grown in Roswell Park Memorial Institute (RPMI)-1640 with 10% fetal bovine serum (Gibco). All cultures were maintained at 37°C in a humidified atmosphere containing 5% carbon dioxide. Olmesartan (2.0 mM, Daiichi Sankyo Pharmaceutical) was dissolved in dimethylsulfoxide just before use. The cells were cultured with and without Ang II (0.1 μM) or olmesartan at the time of seeding to examine olmesartan influence on cervical cancer cells.
Quantitative reverse transcription-polymerase chain reaction (qRT-PCR)
Quantification of miR-205 expression levels was assessed via qRT-PCR using specific TaqMan ® assays according to the instructions of the manufacturer (Applied Biosystems). U6 RNA was used as normalizer.
Proliferation assay
The transfected cells were seeded in 96-or six-well plates and cultured for 48 hours. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed to test cell proliferation. For clonogenic assay, cells were plated at a final concentration of 200 cells/ml. Colonies were counted after staining the cells with 0.1% crystal violet within 10 days after plating. Each experiment was conducted in triplicate.
Invasion assay
Cell invasion assay was performed using Transwell cell culture inserts (Corning). Cells (1 × 10 5 ) were cultured onto a Matrigel-coated membrane matrix present in the insert of a 24-well culture plate for 24 hours at 37°C. At the end of incubation, the noninvasive cells were removed. Invasive cells were fixed, stained with crystal violet, and photographed under microscope.
DNA construction
miR-205 mimics, control mimics, miR-205 locked nucleic acids (LNA), and control LNA were synthesized by Shanghai Genepharma Co. Ltd. (China). VEGF-A-specific short hairpin RNAs (shRNAs) were generated using oligonucleotide annealing and inserted into pSilencer 2.0 upon BamHI/ HindIII restriction. The shRNA sequence was as follows: Forward, 5'-GATCCGCACAGACTCGCGTTGCAAGTTCA AGAGACTTGCAACGCGAGTCTGTGTTTTTTGGAAA-3';Reverse,5'-AGCTTTTCCAAAAAACACAGACTCGC GTTGCAAGTCTCTTGAACTTGCAACGCGAGTCTG TGCG-3'. VEGF-A CDS and full-length VEGF-A with target 3' UTR fragment were obtained from HEK293 cell cDNA library and constructed into pcDNA3.1 plasmid using BamHI/EcoRI restriction. The primers of VEGF-A CDS were as follows:
The primers of full-length VEGF-A with target 3' UTR were as follows:
Reverse, 5'-CCGGAATTCAGTGCTCTGCGCAGAG TCTC-3'. The oligonucleotide (1 to 180) of VEGF-A 3' UTR was synthesized and inserted into pmirGLO luciferase plasmid using PmeI and XbaI restrictions.
Western blot
Cells were lysed in radioimmunoprecipitation assay lysis buffer containing proteinase inhibitors (Roche). Whole-cell lysates were analyzed using Western blot with anti-VEGF-A polyclonal antibody (Abcam) at a ratio of 1:1000 after being subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The expression of glyceraldehyde-3-phosphate dehydrogenase (GADPH) was used as a loading control and was detected using an anti-GADPH polyclonal antibody (Abcam). Enhanced chemiluminescence method was used to determine protein expression.
Statistical analysis
All data in the current study were evaluated using SPSS 16.0 (SPSS Inc, USA). Data were presented as mean ± SEM and were compared by Student t test or analysis of variance (ANOVA) followed by a post-Student-NewmanKeuls (SNK) q test as appropriate. Differences were considered significant at p < 0.05. 
Results
Effect of olmesartan on VEGF-A and miR-205 expression exposed to Ang II in cervical cancer cells
Olmesartan inhibits cervical cancer cell proliferation and regulates miR-205 and VEGF-A expression
MTT screening analysis of olmesartan demonstrated a strong inhibitory effect on HeLa and Siha cells (Figure 2 ). HeLa and Siha cells were treated with increasing concentrations of olmesartan. A concentration-dependent inhibition of proliferation was evident at 0.5, 1.0, 1.5, 2.0 and 2.5 mM, as demonstrated using an MTT proliferation assay. MiR-205 and VEGF-A expression levels were identified using miRNA-specific RT-PCR and Western blot analysis to determine the mechanism of olmesartan inhibition of cervical cancer cells. miR-205 was significantly upregulated and VEGF was significantly downregulated after treatment with 0.5-3.0 mM olmesartan.
miR-205 and VEGF-A regulate cervical cancer cell proliferation
miR-205 mimics and VEGF-A shRNA plasmid were separately transfected into HeLa and Siha cells to validate further the function of miR-205 and VEGF-A in cervical cancer cell proliferation. Colony formation assay and invasion assay were performed to assess the effect on cervical cancer cells. As shown in Figure 3 , invasive and colony formation capability was strongly inhibited after miR-205 overexpression or VEGF-A downregulation compared with the control.
miR-205 targets VEGF-A
Bioinformatics database (Targetscan) and luciferase reporter assay were used to examine the relationship between miR-205 and VEGF-A. As shown in Figure 4 
Discussion
miR-205 is a well-known tumor suppressor in almost all cancers. However, despite the role of miR-205 in cancer 22, 23 and the dedication of researchers to the validation of the molecular mechanisms involved in cancer development, the role of miR-205 in cancer drug therapy remains largely unexplored. In the current study, results indicate the dysregulation of miR-205 in cervical cancer cells treated by olmesartan. Genes involved in cancer anti-drug progress include oncogene and anti-tumor genes. Although miRNAs are small non-coding RNAs, they can control tumor genesis, proliferation and differentiation by regulating cancerrelated genes. Previous studies have shown that miR-20a contributes to chemotherapeutic resistance in colorectal adenocarcinoma by targeting BCL2 interacting protein 2 (BNIP2). 24 High expression levels of miR-21 contribute to breast cancer drug resistance of Trastuzumab. 25 In the present study, upregulation of miR-205 in cervical cancer cells treated with olmesartan was compared with untreated cells. In addition, VEGF-A as a target gene of miR-205 was validated using luciferase reporter assay. Overexpressions of miR-205 and knockdown of VEGF-A contributed to olmesartan-induced anti-tumor effect on cervical cancer cells.
Although early studies by Xie and Ma 26, 27 showed that the expression of miR-205 was higher in cervical cancer tissue and cell lines ME-180, C4I and CaSki, while low expression/barely detectable levels were found in HeLa, SW756, SiHa and C33A. This was similar to our results.
Several in vivo and in vitro studies have revealed that renin-angiotensin system (RAS) inhibitors had antitumor properties. 28, 29 Antiangiogenic drugs (ADs) are one of the key components of frontline therapy in current combination regimens for the treatment of various human cancers. Clinical experiences gained from handling different types of cancers demonstrate that ADs, such as sorafenib, bevacizumab, and sunitinib, in combination with chemotherapy, often produce significant but modest survival benefits. 30, 31 These clinical findings have raised several important issues regarding the beneficial mechanisms of antiangiogenic therapy in cancer patients. [32] [33] [34] In the current study, olmesartan inhibits tumor cell invasion, and it also has the capability to suppress VEGF-A secretion. Further studies have shown that through miR-205, olmesartan can regulate VEGF-A expression. They also suggest that VEGF-A may be a regulation target of miR-205, which reveals more about the molecular mechanism of olmesartan as an AD. See Figure 6 .
The current study suggests that olmesartan inhibits cervical cancer cell proliferation and may serve as a therapeutic option against cervical cancer that might be mediated by upregulating miR-205 and regulate the expression level of VEGF-A. A new mechanism of Ang II receptor blocker (ARB), olmesartan, on anti-tumor therapy was illustrated, which may be useful for further application for human cervical cancer treatment.
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